top of page

Biopharma Daily Stock Updates - 08/11/21

$XBI $125.66 -0.70%


Covid Updates

$SRNE +0.70% Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics source

$VALN -4.2% Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate source

Pipeline Updates

$CLNN +0.80% Clene Enters into Two Leases to Materially Expand Manufacturing Capacity of its Lead Asset CNM-Au8® source

$AKUS -3.0% Akouos Announces European Commission Designation of AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss as an Orphan Drug source

$FGEN -5.8% FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease source

$SMMT -4.0% Summit Therapeutics Provides Update on Ri-CoDIFy Trials source

$LTRN -2.5% FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer source

$ANVS -8.1% Annovis Bio Completes Dosing Of Parkinson’s Disease Patients With Anvs401 In Phase 2a Clinical Trial source

$AZN +0.4% Update on US regulatory review of roxadustat in anaemia of chronic kidney disease source

$PSTV +11.2% Plus Therapeutics To Present Data From Two Studies Supporting The Treatment Of Leptomeningeal Metastases With Rhenium-186 Nanoliposome source

$CCCC -2.2% C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma source

$TPTX -0.40% Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib source

$XERS +1.7% Xeris Pharmaceuticals Announces Fda Acceptance Of Its Ind Application For Xerisol™ Levothyroxine (Xp-8121) For The Treatment Of Hypothyroidism source


Posted by JM

bottom of page